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Background: The decline of cognitive processing speed (CPS) is a common dysfunction in persons with multiple sclerosis
(MS). The Symbol Digit Modalities Test (SDMT) is widely used to formally quantify CPS. We implemented a variant of the
SDMT in MS sherpa, a smartphone app for persons with MS.
Objective: The aim of this study was to investigate the construct validity and test-retest reliability of the MS sherpa smartphone
variant of the SDMT (sSDMT).
Methods: We performed a validation study with 25 persons with relapsing-remitting MS and 79 healthy control (HC) subjects.
In the HC group, 21 subjects were matched to the persons with MS with regard to age, gender, and education and they followed
the same assessment schedule as the persons with MS (the “HC matched” group) and 58 subjects had a less intense assessment
schedule to determine reference values (the “HC normative” group). Intraclass correlation coefficients (ICCs) were determined
between the paper-and-pencil SDMT and its smartphone variant (sSDMT) on 2 occasions, 4 weeks apart. Other ICCs were
determined for test-retest reliability, which were derived from 10 smartphone tests per study participant, with 3 days in between
each test. Seven study participants with MS were interviewed regarding their experiences with the sSDMT.
Results: The SDMT scores were on average 12.06% higher than the sSDMT scores, with a standard deviation of 10.68%. An
ICC of 0.838 was found for the construct validity of the sSDMT in the combined analysis of persons with MS and HC subjects.
Average ICCs for test-retest reliability of the sSDMT for persons with MS, the HC matched group, and the HC normative group
were 0.874, 0.857, and 0.867, respectively. The practice effect was significant between the first and the second test of the persons
with MS and the HC matched group and trivial for all other test-retests. The interviewed study participants expressed a positive
attitude toward the sSDMT, but they also discussed the importance of adapting a smartphone cognition test in accordance with
the needs of the individual persons with MS.
Conclusions: The high correlation between sSDMT and the conventional SDMT scores indicates a very good construct validity.
Similarly, high correlations underpin a very good test-retest reliability of the sSDMT. We conclude that the sSDMT has the
potential to be used as a tool to monitor CPS in persons with MS, both in clinical studies and in clinical practice.
(JMIR Mhealth Uhealth 2020;8(10):e18160) doi: 10.2196/18160
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Introduction
Background
Multiple sclerosis (MS) is a chronic disease in which the body’s
immune system mistakenly attacks the isolating sheath (myelin)
that surrounds the nerve fibers in the central nervous system.
MS may affect the brain, the spinal cord, and the optic nerves,
and disrupt the information flow across the affected nerves.
This may cause a variety of symptoms, including loss of vision
(optic neuritis), muscle weakness, sensory symptoms, cognitive
dysfunction, altered coordination, and fatigue. For most persons
with MS, sudden relapses contribute to the unpredictability of
the disease, which makes it difficult to devise a treatment plan
specific to an individual patient.
The prevalence of cognitive dysfunction in persons with MS is
estimated to be between 40% and 70%, depending on the
research setting [1-4]. This can include dysfunction in
visuospatial processing, cognitive processing speed (CPS),
working memory, executive functioning, verbal and visual
learning, as well as episodic memory. CPS decline is among
the first cognitive signs and the most commonly observed
cognitive deficit in persons with MS. Importantly, CPS decline
has a significant impact on the quality of life [3,5]. CPS is
usually assessed by measuring the amount of information
processed in a unit of time or the time needed to process a given
amount of information.
The Paced Auditory Serial Addition Test (PASAT) [6] and the
Symbol Digit Modalities Test (SDMT) [7] are the most widely
used tests to formally quantify CPS in MS, and they focus on
auditory CPS and visuospatial CPS, respectively [8-10]. Both
are included in the Rao Brief Repeatable Battery of
Neuropsychological tests, amongst tests for learning and
executive function. Sometimes, the Brief Repeatable Battery
of Neuropsychological tests is administered by clinicians during
check-ups [2,11]. Both tests are part of the Minimal Assessment
of Cognitive Function [12]. Notably, the more compact Brief
International Cognitive Assessment for MS (BICAMS) test
battery prefers SDMT over PASAT [13]. The SDMT score has
a strong correlation with the Expanded Disability Status Scale
(EDSS) score [14]—a stronger correlation than the PASAT
scores [15,16]—as well as with abnormalities seen in magnetic
resonance images such as in brain lesion volume, cerebral
atrophy, diffusion tensor indices of normal appearing brain
tissue, and retinal nerve fiber layer thickness [17]. Although
both the PASAT and SDMT are highly sensitive in detecting
cognitive impairment, the SDMT has higher acceptability among
patients, is easier to administer, and has slightly higher
sensitivity than PASAT [13,15]. Moreover, findings suggest
that the SDMT more accurately reflects the qualitative nature
of self-reported cognitive impairment and should perhaps replace
the PASAT as part of the MS Functional Composite (MSFC)
[18]. Finally, the SDMT has been found to be relatively resistant
to practice effects and is therefore useful for serial testing and
screening [19].
Although the SDMT has been proven to be clinically relevant,
it is not regularly used in standard care. This is partly because
patients often do not complain about cognitive changes during
consultation with a health care professional. It is also because
of the time factor and administrative burden, despite the
relatively short duration of one assessment, that is, 90 seconds.
Paper-and-pencil variants of the SDMT have been existing for
quite some time [20,21], but digital variants have been
developed only in recent years for computers [18], tablets
[22,23], or smartphones [24,25]. It is believed that e-versions
will make it easier to monitor CPS. However, to our knowledge,
no scientific papers about the validity of the smartphone variants
of the SMDT have been published to date.
MS sherpa (Orikami Digital Health Products) is a smartphone
app intended to support the monitoring of persons with MS, in
order to give patients and their health care professionals
personalized insight into the presence and progress of
MS-related symptoms and signs. MS sherpa contains a
smartphone variant of the SDMT (sSDMT). This sSDMT works
as follows: a large black symbol present in the middle of the
screen has to be matched to the correct digit. Matching can be
done at the bottom of the screen. Once an answer is given, a
new symbol appears. The sSDMT score is the number of correct
answers in this 90-second test. A small stopwatch counting
down is shown above the numbers at the bottom of the screen.
The key is shown at the top of the screen. The same key is used
during 1 assessment, but it varies between assessments; the
symbols are randomly matched to digits in the key each time a
test is done. These symbols are different from those in the
original SDMT since these are protected by copyrights.
Note that contrary to the original SDMT, in sSDMT, one cannot
look ahead as to which symbol is to be matched next. However,
also in the original SDMT, skipping a symbol in the presented
sequence is not allowed. There are 2 other aspects in which the
sSDMT differs from the SDMT. First, in the original SDMT,
the first 26 items are selected from the first 6 symbols in the
key. In the sSDMT, symbols are selected from the full key
during the whole assessment. This was also the case in the first
version of other alternative versions of the SDMT [5]. Second,
instead of using the first 10 “practice” items that can be matched
with guidance in the original SDMT, it is possible to practice
the sSDMT by pressing the corresponding button on the
instruction screen. In a practice test, symbols are again randomly
matched to digits in the key, which is therefore different from
the key in the “real” sSDMT. The rationale for not matching
exactly the “practice” phase to the original SDMT was that
home monitoring can be done frequently and practicing before
every test should not be mandatory, from a usability perspective.
Objective
We aimed to study the construct validity and test-retest
reliability of the sSDMT that is implemented in MS sherpa as
an assessment for CPS and present our findings in this paper,
along with respondents’ experiences with the sSDMT. The
validation of the sSDMT was part of the MS Self study. The
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MS Self study was a validation study during which study
participants performed self-monitoring assessments during 4
weeks with a precursor of MS sherpa, which was called the
“Mijn Kwik” app and a Fitbit Charge 2 wearable. Besides
investigating the validity of the sSDMT, another research
objective of the MS Self study was to investigate first the
experiences with digital self-monitoring through smartphone
apps and activity trackers of persons with MS by interviewing
7 study participants with MS. Furthermore, the study aimed to
validate a smartphone variant of the 2-minute walking test
(s2MWT) and a smartphone walking balance test (sWBT). In
particular, we investigated if the outcomes of the smartphone
tests were in agreement with the outcomes of corresponding
clinical tests, namely, SDMT, the 2-minute walking test
(2MWT), and the Timed Up and Go test (TUG). The other
results from the interviews as well as a description of the
methodology have recently been published [26]. Separate
research papers on the s2MWT, the sWBT, and the Fitbit data
are in preparation. A poster with the preliminary results of the
MS Self study [27] can be found on the MS sherpa website [28].
This poster also contains an image of the sSDMT.
Methods
Study Design
This study was performed in 25 persons with relapsing-remitting
MS and 2 groups of healthy control (HC) subjects (n=79). The
HC subjects in the first control group (HC matched, n=21) were
matched to the persons with MS with regard to age, gender, and
education. Five education categories were defined: “secondary
general education,” “senior secondary general education and
preuniversity education,” “secondary vocational education,”
“higher professional education,” and “scientific education”. The
second control group (HC normative, n=58) was set up to
determine the normal distribution for the smartphone test results.
The inclusion criteria were as follows: (1) willing to participate
and capable of doing all the tasks mentioned in the protocol,
(2) able and willing to use own smartphone, which should be
an iPhone 5 or a newer Apple device, or a phone with an
Android operating system version 6 or higher, and (3) aged
between 20 years and 50 years. For persons with MS, the
following additional inclusion criteria were set: (1) diagnosis
of relapsing-remitting MS for more than one year and (2) having
an EDSS score between 1.5 and 6.5. A maximal EDSS score
of 6.5 is needed to perform the 2MWT. A minimal EDSS score
of 1.5 was chosen to find a difference in the 2MWT results for
persons with MS and HC subjects.
On the first and the last day of the study, persons with MS and
the HC matched group came to the premises of the Dutch
National MS Foundation (Nationaal MS Fonds [NMSF]) to
perform a paper-and-pencil SDMT, followed by a
simultaneously performed 2MWT and a s2MWT in the open
air. Later that day, and at most 24 hours later, they also
performed the sSDMT in their home environment. During the
4-week follow-up, these study participants performed the
s2MWT and sSDMT tests at home, once every 3 days, that is,
10 times in total. A schematic overview of the study design is
given in Figure 1. The EDSS was administered to every person
with MS by MH on the first day of the study.
Figure 1. Overview of the study design and assessment scheme. SDMT: Symbol Digit Modalities Test; 2MWT: 2-minute walking test.
The HC subjects in the HC normative group were instructed to
do the s2MWT and the sSDMT 3 times in total, with 1 week in
between the assessments. From these tests and from the 10 home
assessments of the other study participants, the test-retest
reliability of the sSDMT was determined. The combined test
results “SDMT-sSDMT” for the persons with MS and the HC
matched group were used to determine the construct validity of
the sSDMT. This combination will hereafter be referred to as
the validation assessment. Note that there are 2 validation
assessments per study participant: one in the beginning and one
at the end of the study.
Recruitment
The persons with MS and HC matched group were recruited
via the NMSF (Rotterdam, the Netherlands). The HC normative
group was recruited via the social network of the app
manufacturer.
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Ethical Approval and Informed Consent
This study was approved by the medical ethical committee
METC Brabant (Tilburg, the Netherlands) under protocol
number NL61291.028.17. All study participants agreed to the
privacy statement of the Mijn Kwik app prior to first use.
Persons with MS and the HC matched group signed an informed
consent letter on paper.
Data Collection
Data were collected between May 2017 and May 2018. The
ages of the HC subjects in the HC matched group were matched
as closely as possible to that of the persons with MS, which led
to at most 2 years difference for 86% (18/21) of the pairs.
Approximately 90% (19/21) of the pairs matched in gender. An
exact match in education category was obtained for 29% (6/21)
of the pairs.
Data Analysis
In the analyses performed in this study, the SDMT score on the
first day of the study was compared with the first sSDMT score
and the SDMT score on the last day of the study was compared
with the last sSDMT score. In the data cleaning process of the
sSDMT data, the home assessments in which the study
participants had a score below 20 were removed because these
were outliers. It was assumed that the users were distracted
during these tests. A score below 20 occurred in less than 1%
(3/423) of all the sSDMTs that were done.
Statistical Analysis
Following the study protocol, the significance level α was set
to 5%. Two-sided t tests were conducted to compare the SDMT
score with the sSDMT score. For the smartphone tests, the
median test score of each study participant was taken in the t
test analysis. Internal consistency was evaluated and quantified
using Cronbach α, in which an α value larger than .7 was
defined to be acceptable [29,30]. Test-retest reliability was
determined by calculating the intraclass correlation coefficient
(ICC) between measurements at different times. ICCs smaller
than 0.59 were considered to be “moderate,” ICCs between 0.60
and 0.79 were considered “good,” and ICCs above 0.80 were
considered “very good” [31,32]. The effect size Cohen d was
determined to investigate the practice effect. A Cohen d below
0.20 was seen as trivial [33].
To investigate the construct validity of the sSDMT, we
calculated the (1) ICC between the SDMT and the sSDMT and
the (2) Pearson correlation coefficient between the SDMT and
the sSDMT (the distributions were checked for normality by
applying Shapiro-Wilk tests).
For these statistical tests, we used the same acceptance criteria
as for the test-retest reliability: values smaller than 0.59 were
considered to be “moderate,” values between 0.60 and 0.79
were considered “good,” and values above 0.80 were considered
“very good.”
We calculated different ICCs for the construct validity and the
test-retest reliability, following the McGraw and Wong [34]
convention. Although the “model” selection (two-way mixed
effects) and the “type” selection (single rater/measurement) of
both ICCs are the same, the “definition” (consistency or absolute
agreement) is different [35]. ICCs of type “ICC(3,1)” were
calculated to compare the SDMT and the sSDMT. These ICCs
have definition “consistency,” since these 2 test scores were not
expected to exactly match. ICCs of type “ICC(A,1)” were
calculated to determine test-retest reliability. These ICCs have
definition “absolute agreement,” since the test scores per
individual were not expected to change within the 1-month
follow-up of the study.
We checked if the distributions of the number of correct answers
on the first sSDMT that was done for the 3 populations in this
study were normally distributed via Shapiro-Wilk tests and if
the 2 groups of the HC subjects had the same underlying
distribution via a 2-sample Kolmogorov-Smirnov test. Finally,
we did a two-sided t test to confirm the difference between
persons with MS and HC subjects.
Results
Participant Demographics
The mean, median, and standard deviation in the ages for the
various groups are listed in Table 1, as well as the gender, the
number of participants in each education category (for the HC
normative group, no education information was collected), and
the mean, median, and standard deviation in the EDSS score
(persons with MS).
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Table 1. Participant demographics.
HC normative, n=58HCb matched, n=21Persons with MSa, n=25Characteristics
Age (years)
34 (8)37 (8)40 (8)Mean (SD)
323643Median
Gender
29 (50)17 (81)23 (92)Female, n (%)
29 (50)4 (19)2 (8)Male, n (%)
Education
—c3 (14)1 (4)Secondary general education, n (%)
—3 (14)3 (12)Senior secondary general education and preuni-
versity education, n (%)
—3 (14)8 (32)Secondary vocational education, n (%)
—6 (29)9 (36)Higher professional education, n (%)







dEDSS: Expanded Disability Status Scale.
eN/A: not applicable.
Besides these 104 study participants, 2 more persons were
recruited, but 1 person with MS dropped out of the study
because she was experiencing a relapse and 1 HC dropped out
because she did not like wearing Fitbit.
Distinctions Between Persons with MS and HC
Subjects
Figure 2 shows the number of correct answers for the first
sSDMT in the persons with MS and in the 2 control groups.
The number of correct answers was normally distributed for all
3 groups as calculated by the Shapiro-Wilk tests (P=.49, P=.29,
and P=.37 for persons with MS, the HC matched group, and
the HC normative group, respectively). The 2 groups of HC
subjects have the same underlying distribution as confirmed
using a 2-sample Kolmogorov-Smirnov test
(Kolmogorov-Smirnov statistic=0.26, P=.20). Independent
2-sample t tests between persons with MS versus the HC
matched group and persons with MS versus the HC normative
group confirmed that the sSDMT can distinguish between
persons with MS and HC subjects at the group level (P=.02 and
P<.001, respectively).
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Figure 2. Distributions in the number of correct answers on the first test done with the sSDMT for the 3 groups in this study. The thin solid line shows
the distribution for persons with multiple sclerosis, the dotted line shows the distribution for the healthy control matched group, and the dashed line
shows the distribution for the healthy control normative group. The thick solid lines represent Gaussian fits to the distributions, of which the means
(SD) are shown in the legend. sSDMT: smartphone variant of Symbol Digit Modalities Test.
Construct Validity
Two variants of the conventional SDMT were used in the
validation assessments: the original paper version of the SDMT
[7] (abbreviated as “SDMT”) and a paper version of the sSDMT
(a variant of the SDMT, hereafter referred to as “vSDMT”).
Since the SDMT is copyright protected, the vSDMT was printed
in the study protocol. This was misinterpreted by some members
of the research team (PvO and MH) as an extra variant of the
SDMT to be investigated and was randomly assigned to more
than half of the study participants. Different variants could
therefore be used in the 2 validation assessments of a given
person. Contrary to the regular instructions for an SDMT, study
participants did not get 10 “practice” items to be matched with
guidance in this study neither for the vSDMT nor for the SDMT.
In total, 37 SDMTs and 55 vSDMTs were conducted. In this
section, we present the comparison between the SDMT and the
sSDMT (raw data in Multimedia Appendix 1). The raw data of
the validation assessments with vSDMTs are listed in
Multimedia Appendix 2.
The construct validity was determined from 37 validation
assessments with the SDMT. One of these assessments was the
first validation assessments of a dropout. The vSDMT score of
the first validation assessments of the other dropout is included
in the Multimedia Appendix 2. However, including these
assessments did not increase the total number of validation
assessments since 1 HC subject did 2 invalid SDMTs. This
person did not match the symbols with the digits in the order
of appearance on the sheet of paper, but instead started matching
all symbols of a specific kind first, both on the first and on the
last day of the study.
It was found that, on average, 6.62 less correct answers were
given on the sSDMT than on the SDMT (Figure 3). A
Shapiro-Wilk test on the distribution of the differences accepted
normality (P=.15). This allows us to determine the 95% CI, at
1.96*s around the mean difference, with SD=6.13 correct
answers, which is visualized in the Bland-Altman plot (Figure
4). In this plot, the difference between the 2 tests is shown as a
percentage of the mean of the 2 test outcomes on the vertical
axis, and the mean is shown on the horizontal axis. The number
of correct answers on the sSDMT is, on average, 12.06%
(6.62/54.80) lower than the number of correct answers on the
SDMT (P<.001). The 1.96*s above and below this average
results in a difference of 8.87% more and 33.00% less correct
answers on the sSDMT than on the SDMT, respectively.
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Figure 3. Distribution of the differences between the number of correct answers on the sSDMT and the SDMT. The dashed line represents a normal
distribution. sSDMT: smartphone variant of Symbol Digit Modalities Test; SDMT: Symbol Digit Modalities Test.
Figure 4. Bland-Altman plot of differences between the number of correct answers on the sSDMT and SDMT, expressed as percentages of the mean
value (∆/mean) versus the mean of the 2 measurements (raw data in Multimedia Appendix 1). The dashed line shows the mean percentage difference,
and the dotted lines show the 95% confidence interval. sSDMT: smartphone variant of Symbol Digit Modalities Test; SDMT: Symbol Digit Modalities
Test.
When investigating the agreement between the SDMT and the
sSDMT using a t test, as was planned in the study protocol, a
very small P value was obtained. A dependent t test for paired
samples yielded a test statistic of 6.49 (P<.001). Since this was
below the significance level of .05, we rejected the null
hypothesis of identical average scores. In Figure 5, the number
of correct answers on the sSDMT is plotted against the number
of correct answers on the SDMT. ICCs(3,1) were determined
for persons with MS and HC subjects separately and for the
combined dataset, which are shown in the top left corner of
Figure 5. The Pearson correlation coefficient and the formula
corresponding to the linear fit through the data are also shown
in the top left corner of Figure 5.
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Figure 5. Scatter plot showing the ICCs(3,1) and the correlation (Pearson r, upper left corner) between the number of correct answers on the SDMT
(horizontal axis, “x”) and the sSDMT (vertical axis, “y”). A linear fit through the data points is visualized as a black solid line, for which the formula
is also given in the upper left corner. ICC: intraclass correlation coefficient; sSDMT: smartphone variant of Symbol Digit Modalities Test; SDMT:
Symbol Digit Modalities Test.
For the persons with MS, we checked if the number of correct
answers on the first sSDMT was dependent on the screen size
of their smartphones or their operating systems. The resulting
distributions are respectively shown in the left and right panels
of Figure 6. We took the total number of pixels as an estimate
for screen size. The screens with less than 2 million pixels were
considered small, while those with 2 million pixels or more
were considered large. The number of correct answers was
normally distributed for all 4 categories as calculated by the
Shapiro-Wilk tests (P=.54, P=.48, P=.16, and P=.30 for a small
screen, large screen, iPhone operating system, or Android
operating system, respectively). Since we investigated the score
on the first sSDMT, we also included the test results of the
persons with MS who dropped out of the study. We cannot
confirm if this dropout did not experience difficulties with
perceptual motor abilities, but inclusion of this individual does
not significantly affect the results.
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Figure 6. A: Distribution of the number of correct answers on the first sSDMT of 13 persons with multiple sclerosis who used a smartphone with a
large screen size (dashed line) and 13 persons with multiple sclerosis who used a smartphone with a small screen size (dotted line). The thick solid lines
represent Gaussian fits to the distributions. B: Distribution of the number of correct answers on the first sSDMT of 11 persons with multiple sclerosis
who used a smartphone with an iPhone operating system (iOS) (dotted line) and 15 persons with multiple sclerosis who used a smartphone with an
Android operating system (dashed line). The thick solid lines represent Gaussian fits to the distributions. In both panels, the dot-dashed line represents
a Gaussian fit to the full distribution (both categories). MS: multiple sclerosis; sSDMT: smartphone variant of Symbol Digit Modalities Test.
The 2 categories of screen size as well as the 2 categories of
operating systems had the same underlying distribution as
confirmed using 2-sample Kolmogorov-Smirnov tests
(Kolmogorov-Smirnov statistic for screen size=0.23, P=.83 and
Kolmogorov-Smirnov statistic for operating system=0.28,
P=.60). These distributions are plotted with a dot-dashed line
in both panels of Figure 6. Similarly, independent 2-sample t
tests between the 2 categories of screen size and between the 2
categories of operating systems confirmed that neither the screen
size nor the operating system had an effect on the test score
(P=.98 and P=.46, respectively).
Test-Retest Reliability
One of the dropouts did 7 home assessments with the sSDMT.
We consider this a sufficiently large number to calculate
test-retest reliability; therefore, we included this dropout for the
analyses.
Figure 7A shows the distribution of the total number of home
assessments done for persons with MS and HC matched group.
Even though 57% (27/47) of the persons with MS and HC
subjects in the matched group did more than 10 tests in total,
we included only their first 10 home assessments for the
test-retest reliability calculations, as planned in the study
protocol. Figure 7B shows the distribution of the average
number of days the persons with MS and HC subjects in the
matched group left between tests, which was averaged over all
tests of a study participant. This distribution peaks at 3 days,
but it is different from 3 days for 55% (26/47) of the study
participants. In these histograms, we also show the distributions
of 60% (28/47) of the persons with MS and HC subjects in the
matched group who continued to do tests after 4 weeks. The
scatter plot in the lower right panel of Figure 7 (Figure 7C)
shows the relation between the number of tests done and the
average number of days in between tests. Study participants
who did all home assessments within 28 days are plotted with
filled circles, and the others with open circles.
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Figure 7. A: Histogram showing the distribution of total number of tests done. B: Histogram showing the distribution of number of days in between
tests, averaged over all tests of a study participant. C: Scatter plot that shows the relation between the number of tests done (horizontal axis) and the
average number of days in between tests, averaged over all tests of a study participant (vertical axis) for all study participants. Filled circles correspond
to participants that finished the study within 28 days, open circles correspond to those for which the study duration exceeded 28 days. The blue lines in
panels A and B correspond to these filled circles, and the black lines in panels A and B correspond to the open circles.
The ICCs(A,1) (with their 95% CI), Cronbach α, and Cohen d
values that were derived from 9 test-retests of the sSDMT for
the persons with MS and the HC matched group are listed in
Table 2, and the values of those derived from the 2 test-retests
performed by the HC normative group are shown in Table 3.
The raw data from persons with MS and the HC matched group
can be found in the Multimedia Appendix 3 and that of the HC
normative group in Multimedia Appendix 4. The mean values
of the ICC(A,1) for persons with MS, HC matched group and
the HC normative group were 0.874, 0.857, and 0.867,
respectively.
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Table 2. Test-retest reliability scores ICC(A,1), Cronbach α, and Cohen d of the sSDMT for persons with multiple sclerosis and the healthy control
matched group. The numbers in the parentheses after the ICCs(A,1) indicate lower and upper boundaries of the 95% confidence interval, respectively.
Cohen d of HC sub-
jects
Cohen d of persons
with MS

















aICC: intraclass correlation coefficient.
bMS: multiple sclerosis.
bHC: healthy control.
Table 3. Test-retest reliability scores ICC(A,1), Cronbach α, and Cohen d of the sSDMT for the healthy control normative group. The numbers in the
parentheses after the ICCs(A,1) indicate the lower and upper boundaries of the 95% CI, respectively.
Cohen dCronbach αICCa(A,1)Test-retest
0.201.9430.877 (0.772-0.931)sSDMTb test-retest 1
0.116.9250.857 (0.769-0.913)sSDMT test-retest 2
0.159.9340.867 (0.771-0.922)mean
aICC: intraclass correlation coefficient.
bsSDMT: smartphone variant of Symbol Digit Modalities Test.
As was planned, we quantified the practice effect using the
effect size Cohen d, with a value below 0.20 being trivial
(Cohen, 1988). The Cohen d values in Table 3 show that there
is a significant practice effect after the first sSDMT for all study
participants. When comparing the first and second sSDMT
scores of the persons with MS and HC subjects in the matched
group, we found that the mean increase in the number of correct
answers in the second test was 3.38 points or 6.87% compared
to the first test. Toward the end of the study, the practice effect
on the sSDMT completely disappeared at group level. For
example, there was, on average, no difference in the scores
between the seventh and the eighth sSDMT.
Study participants performed better on the SDMT on the last
day of the study, on average, compared to their score on the
first day of the study. The average increase between these 2
tests was 5.57%, with a standard deviation of 11.40%, as can
be calculated for the 14 study participants that did the SDMT
both at the first and at the last day of the study, and even
differences as high as 34.92% are reached. Comparing the first
and last sSDMT for these 14 study participants yielded, on
average, an increase in the number of correct answers of 11.77%,
with a standard deviation of 7.84%. The Cohen d values
quantifying the practice effect on the SDMT and the sSDMT
between the first and the last day of the study were found to be
0.365 and 0.908, respectively. The practice effect for the HC
normative group was also investigated. The Cohen d values
corresponding to the first and the second retest were found to
be 0.201 and 0.116 respectively (see Table 3). Although a mean
increase in the test score of 3.32% at group level was found
between the first and the second test with a standard deviation
of 7.29%, the practice effect could be considered trivial for this
group on the basis of the Cohen d values.
Interview Results
The 7 participants with MS who were interviewed about their
experiences with the smartphone app and Fitbit activity tracker
in general expressed a positive attitude regarding sSDMT. They
liked doing the test, often describing it as a “game” or a
“puzzle.” Moreover, 5 respondents imagined that this test could
provide valuable information to health care providers about the
health status of their patients, as this is relevant information
about how their patients are doing. Despite this general positive
attitude, respondents also expressed some remarks regarding
the sSDMT. Two respondents noticed that sometimes the digits
they pressed did not seem to respond. They were unsure whether
this was caused by the app or their phone. Furthermore, several
respondents discussed that in order to use a smartphone
cognition test in their daily life, such a test should become
personalized. Three respondents mentioned that every person
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with MS has different difficulties regarding cognition and felt
that these differences could not be captured by a single test.
Rather, they envisioned a smartphone app with multiple
cognition tests from which persons with MS can choose from,
depending on their personal cognitive issues. Another point of
personalization concerned the test frequency. Four respondents
expected that during the stable periods of their MS, they would
feel less need to perform the sSDMT than during periods of
relapse. Therefore, they desired flexibility in the sSDMT test




We found that the sSDMT can distinguish between persons
with MS and HC subjects at the group level. The test scores on
the sSDMT are, on average, 12.06% lower than that on the
paper-and-pencil SDMT. Although there is no exact agreement
between the sSDMT and the SDMT, the 2 tests are strongly
correlated, with ICC(3,1) values of 0.784 and 0.852 for persons
with MS and HC subjects, respectively. The sSDMT shows
very good test-retest reliability, with average ICCs of 0.874,
0.857, and 0.867 for persons with MS, the HC matched group,
and the HC normative group, respectively. The practice effect
was significant between the first and the second test of the
persons with MS and the HC matched group and trivial for all
other test-retests. A positive attitude toward the sSDMT was
found during the interviews with study participants with MS.
Importantly, interview respondents expressed the desire to adapt
smartphone cognition tests according to the individual needs
of persons with MS, with regard to both the type and frequency
of testing.
Limitations
The SDMT is a relevant tool both for screening and monitoring
not only for MS but for many other clinical diseases such
as Huntington disease, Parkinson disease, and stroke [36]. This
study limits itself to persons with MS, and the validity of the
sSDMT will still have to be demonstrated for applications
outside MS. The validation and study population are limited to
Dutch people and the Dutch language. We expect that the
construct validity and test-retest reliability would have been
equally good if this study had been done with persons with MS
from various European countries, given the validity and
reliability that were found in studies in populations from various
countries with other digital assessment devices for CPS. The
MS sherpa app now also supports an English version of the
sSDMT, and a German version is planned. However, we
recommend a separate validation for each country where the
sSDMT will be used, for example, as done for BICAMS [37,38]
because the SDMT is known to be affected by culture [39]. It
was not expected that the number of correct answers on the
sSDMT and the SDMT would exactly match, because the
sSDMT was not designed to follow the SDMT as close as
possible, and systematic differences between the tests exist.
Therefore, the SDMT and sSDMT may not be used
interchangeably for monitoring. The lower scores on the sSDMT
compared to the SDMT are most likely caused by the fact that
all items of the sSDMT are selected from the full key, whereas
in the SDMT, the first 26 items are selected from the first 6
symbols in the key only.
A 10% difference between 2 SDMT scores of a patient is found
to be an indication of a clinically meaningful change in the
patients’ CPS [8]. This study was not designed to derive the
boundary for meaningful change on the sSDMT score. Even
though there is a strong correlation between the SDMT and the
sSDMT, we cannot claim that a 10% difference on 2 sSDMT
scores also signifies a clinically meaningful change. Moreover,
we found more than 10% increase in sSDMT performance
between the first and the last day of the study, on average, even
though the disability of the persons with MS was not expected
to change during the 4 weeks of follow-up. An explanation for
this increase and for the Cohen d value quantifying the practice
effect on the sSDMT between the first and the last day of the
study of 0.908 is that 60% (28/47) of the study participants had
been learning on the sSDMT every 3 days or more often, leading
to accumulations of learning effects.
One might wonder how often an sSDMT could be scheduled,
to keep its value as an objective instrument for measuring CPS.
Benedict et al [19] showed that the SDMT has good-to-excellent
reproducibility over repeated testing when used in monthly
successive examinations. The HC subjects in the normative
group who had a time of 1 week between tests instead of 3 days
had less of a practice effect than the persons with MS and HC
subjects in the matched group. Therefore, when trying to
minimize the practice effect, the scheduling frequency of
self-assessments should be considered for clinical practice. Our
current suggestion would be to schedule the sSDMT once a
month to avoid inducing large practice effects when supporting
monitoring for clinical practice.
This study was not set up to cross-device validate the sSDMT,
but we have tried to give some sense of the validity over
different screen sizes and the main software platforms, because
we believed that these 2 factors could affect the results. In our
study, we found an approximately equal number of study
participants using the Android or iPhone operating system
platform, which gave us the opportunity to significantly show
that there is no structural bias in using any of the platforms. A
more structural approach to cross-device validation and more
detailed analysis of the performance over different devices could
help to detect validity issues in different devices.
In our study, we did not explicitly give the instructions to
self-monitor under the same conditions each time as much as
possible (preferably in a quiet room). We expect that such
instructions would improve the test-retest reliability. The fact
that the ICCs and Cronbach α values of the first test-retest of
the persons with MS and the HC matched group were lower
than all following 8 can likely be explained by the fact that there
is, in general, a large practice effect between the first and the
second time a cognitive test is done, especially with only 3 days
in between the tests. This is also reflected in the Cohen d values,
which are the highest for the first test-retest. We explain the
triviality of the Cohen d values corresponding to the first and
the second retest of the HC normative group with the larger
time in between successive tests (approximately 1 week).
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The fact that 60% (28/47) of the persons with MS and HC
subjects in the matched group continued to do home assessments
after 4 weeks might be because the end day of the study could
often not be planned 4 weeks after the first day. It could also
be a sign of high acceptance of the sSDMT, as expressed by the
interviewed study participants. These results, together with the
qualitative findings that participants liked doing the sSDMT,
often describing it as a “game” or a “puzzle,” support that the
sSDMT was viewed as “game-like” and confirms that the
sSDMT is well-designed for the user.
Since persons with MS were asked to write down their answers
on the paper-and-pencil SDMT themselves, persons with MS
who had limited hand dexterity might perform lower on the
paper-and-pencil SDMT than those with the same CPS without
hand dexterity problems. There was no Nine Hole Peg Test
scheduled in this study to investigate this possible bias. During
the sSDMT, persons with MS are asked to tap the correct
answer. We expect hand dexterity problems to be less of a
problem for tapping on a smartphone than for writing down a
number on paper. An alternative solution for this bias would be
an oral sSDMT, which should then be validated against an oral
SDMT. However, persons with MS might not find this a natural
way of self-monitoring.
The number of study participants for which the test-retest
reliability of the paper-and-pencil SDMT could be studied was
relatively low, because 2 different versions of the
paper-and-pencil SDMT were used. Although the reliability of
the paper-and-pencil SDMT is well known in literature, it would
have been interesting to study the practice effect of frequently
performing our sSDMT on the paper-and-pencil SDMT in more
detail.
Finally, an important limitation is the omission of the 10
mandatory practice items on the paper-and-pencil SDMT. This
could have introduced a bias toward a better correlation with
the sSDMT, because in the digital variant, practicing is optional,
and therefore it might affect our construct validity. The construct
validity should therefore ideally be reevaluated in a follow-up
study in which study participants do the standard 10 practice
items on the paper-and-pencil SDMT.
As mentioned in the Introduction, originally our rationale for
an optional practice assessment was that practicing should not
be mandatory for persons with MS that do the sSDMT
repeatedly from a usability perspective. Practicing was optional
but could be done unlimitedly by pressing the corresponding
button on the instruction screen. However, our results have let
us to reconsider this perspective and we now believe that the
sSDMT nor a practice session should be accessible unlimitedly,
because of the accumulative nature of the practice effect.
However, when the sSDMT is scheduled only once a month,
users might want to practice before each digital assessment.
Therefore, we currently suggest 10 mandatory practice items
before each digital assessment, which is also more similar to
the paper-and-pencil SDMT, and therefore might improve the
construct validity.
Comparison With Prior Work
A fair number of computerized neuropsychological assessment
devices for monitoring cognitive impairment in MS has been
developed in recent years. A recent systematic review of the
literature on test batteries and single tests with good evidence
for reliability and validity yielded 44 CPS tests, of which all
computerized tests based on SDMT correlated with the
conventional SDMT, with correlation coefficients ranging from
0.75 to 0.88 [40]. Our correlation coefficient of 0.85 is in line
with these findings. Most CPS tests also showed acceptable
reliability, for example, ICC values of 0.88 and 0.97 were
reported for the Processing Speed Test (PST) [41] and the
computerized version of SDMT [18], respectively. The 95% CI
on the mean ICC that we find ranges from 0.717 to 0.945. This
is thus also similar to that reported in prior work.
To our knowledge, there are 2 other smartphone-based SDMT
apps for MS that should be mentioned as alternative solutions
to monitor CPS. One is MSCopilot [24], which contains a digital
SDMT variant and 3 other digital variants of tests in the MSFC.
However, results were only reported for the combined digital
MSFC assessment in comparison to MSFC z-scores. Data on
the validity and reliability of their digital SDMT variants
specifically have never been published to our knowledge.
FLOODLIGHT [25] is another smartphone monitoring app for
persons with MS, which was developed by Roche. At a poster
presented at the European Committee for Treatment and
Research in Multiple Sclerosis in 2018, Montalban et al [25]
reported a Spearman’s correlation of 0.615 between the
FLOODLIGHT smartphone-based SDMT and the conventional
in-clinic outcome measure (oral SDMT). This is considerably
lower than our correlation coefficients (ie, Pearson r=0.85).
Well-validated digital assessment devices for CPS screening
include the PST and the recently introduced Multiple Screener
tool, which contains a digital SDMT for which an ICC of 0.79
between digital and paper-and-pencil-based assessment was
reported [42]. Rudick et al [23] reported a Pearson correlation
coefficient of 0.80 between the PST and analogous technician
tests and concordance correlation coefficients to quantify
test-retest reproducibility of 0.853 for the technician and 0.867
for persons with MS. Our results are similar to theirs. However,
both the PST and Multiple Screener are only available for iPads
and are intended to be used for monitoring CPS in a more
controlled setting (in the clinic), whereas the MS sherpa app is
intended to be used for home monitoring. The importance of
personalization and customization of smartphone apps for
persons with MS has been noted in other studies [43,44]. It is
therefore recommended that the needs and context of the
individual with MS are taken into account in the design of apps
for persons with MS.
To our knowledge, this is the first study in which a smartphone
variant of the SDMT that can be done unsupervised was
cross-platform validated. We obtained valuable novel insights
into frequent home monitoring with the SDMT such as the
observation that the practice effect was only nontrivial between
the first and second sSDMT (with 10 assessments scheduled
and approximately 3 days in between each assessment) but also
about the cumulative practice effects that are involved.
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Furthermore, we believe the qualitative insights obtained from
patient interviews on the needs and wishes of smartphone-based
home monitoring using sSDMT can inspire developers,
caregivers, and researchers for future developments.
Conclusion
This study shows the construct validity of the sSDMT since the
ICCs(3,1) between the SDMT and the sSDMT for persons with
MS and HC subjects were 0.78 and 0.85, respectively. The
sSDMT does have very good test-retest reliability because only
the first test-retest of the persons with MS and the HC matched
group yielded an ICC(A,1) smaller than 0.80. All the other ICCs
were higher than 0.80, both for persons with MS and for HC
subjects. We conclude that the sSDMT has the potential to be
used as a tool to monitor CPS in persons with MS, both in
clinical studies and in clinical practice.
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